These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
228 related items for PubMed ID: 7509318
1. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG. Alonso de Velasco E, Verheul AF, van Steijn AM, Dekker HA, Feldman RG, Fernández IM, Kamerling JP, Vliegenthart JF, Verhoef J, Snippe H. Infect Immun; 1994 Mar; 62(3):799-808. PubMed ID: 7509318 [Abstract] [Full Text] [Related]
2. Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice. Jansen WT, Hogenboom S, Thijssen MJ, Kamerling JP, Vliegenthart JF, Verhoef J, Snippe H, Verheul AF. Infect Immun; 2001 Feb; 69(2):787-93. PubMed ID: 11159969 [Abstract] [Full Text] [Related]
7. Higher Cytokine and Opsonizing Antibody Production Induced by Bovine Serum Albumin (BSA)-Conjugated Tetrasaccharide Related to Streptococcus pneumoniae Type 3 Capsular Polysaccharide. Kurbatova EA, Akhmatova NK, Zaytsev AE, Akhmatova EA, Egorova NB, Yastrebova NE, Sukhova EV, Yashunsky DV, Tsvetkov YE, Nifantiev NE. Front Immunol; 2020 Feb; 11():578019. PubMed ID: 33343566 [Abstract] [Full Text] [Related]
8. A Streptococcus pneumoniae Type 2 Oligosaccharide Glycoconjugate Elicits Opsonic Antibodies and Is Protective in an Animal Model of Invasive Pneumococcal Disease. Emmadi M, Khan N, Lykke L, Reppe K, G Parameswarappa S, Lisboa MP, Wienhold SM, Witzenrath M, Pereira CL, Seeberger PH. J Am Chem Soc; 2017 Oct 18; 139(41):14783-14791. PubMed ID: 28945368 [Abstract] [Full Text] [Related]
9. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Theilacker C, Coleman FT, Mueschenborn S, Llosa N, Grout M, Pier GB. Infect Immun; 2003 Jul 18; 71(7):3875-84. PubMed ID: 12819072 [Abstract] [Full Text] [Related]
10. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Wessels MR, Paoletti LC, Rodewald AK, Michon F, DiFabio J, Jennings HJ, Kasper DL. Infect Immun; 1993 Nov 18; 61(11):4760-6. PubMed ID: 8406875 [Abstract] [Full Text] [Related]
11. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Sorensen RU, Leiva LE, Giangrosso PA, Butler B, Javier FC, Sacerdote DM, Bradford N, Moore C. Pediatr Infect Dis J; 1998 Aug 18; 17(8):685-91. PubMed ID: 9726341 [Abstract] [Full Text] [Related]
12. Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14. Safari D, Dekker HA, Joosten JA, Michalik D, de Souza AC, Adamo R, Lahmann M, Sundgren A, Oscarson S, Kamerling JP, Snippe H. Infect Immun; 2008 Oct 18; 76(10):4615-23. PubMed ID: 18678667 [Abstract] [Full Text] [Related]
13. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Soininen A, Seppälä I, Nieminen T, Eskola J, Käyhty H. Vaccine; 1999 Apr 09; 17(15-16):1889-97. PubMed ID: 10217586 [Abstract] [Full Text] [Related]
14. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Ahman H, Käyhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J. Pediatr Infect Dis J; 1996 Feb 09; 15(2):134-9. PubMed ID: 8822286 [Abstract] [Full Text] [Related]
15. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Chu RS, McCool T, Greenspan NS, Schreiber JR, Harding CV. Infect Immun; 2000 Mar 09; 68(3):1450-6. PubMed ID: 10678959 [Abstract] [Full Text] [Related]
16. B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. McCool TL, Harding CV, Greenspan NS, Schreiber JR. Infect Immun; 1999 Sep 09; 67(9):4862-9. PubMed ID: 10456942 [Abstract] [Full Text] [Related]
17. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Anttila M, Eskola J, Ahman H, Käyhty H. Vaccine; 1999 Apr 09; 17(15-16):1970-7. PubMed ID: 10217596 [Abstract] [Full Text] [Related]
18. Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3. Snippe H, van Houte AJ, van Dam JE, De Reuver MJ, Jansze M, Willers JM. Infect Immun; 1983 Jun 09; 40(3):856-61. PubMed ID: 6852923 [Abstract] [Full Text] [Related]
19. Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Lefeber DJ, Benaissa-Trouw B, Vliegenthart JF, Kamerling JP, Jansen WT, Kraaijeveld K, Snippe H. Infect Immun; 2003 Dec 09; 71(12):6915-20. PubMed ID: 14638780 [Abstract] [Full Text] [Related]
20. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. O'Brien KL, Steinhoff MC, Edwards K, Keyserling H, Thoms ML, Madore D. Pediatr Infect Dis J; 1996 May 09; 15(5):425-30. PubMed ID: 8724065 [Abstract] [Full Text] [Related] Page: [Next] [New Search]